Francesco Bertoni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Francesco Bertoni has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Chiara Tarantelli
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
1 shared publication - Lisa Argnani
Dipartimento di Scienze Mediche e Chirurgiche (DIMEC) Alma Mater Studiorum Università of Bologna Bologna Italy
1 shared publication - Pier Luigi Zinzani
IRCCS Azienda Ospedaliero‐Universitaria di Bologna. Istituto di Ematologia “Seràgnoli”, Azienda Ospedaliero‐Universitaria di Bologna ‐ IRCCS Bologna Italy
1 shared publication
Latest Publications
- Open Access
PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma patients and PI3Kδ inhibitors are already approved by regulatory agencies. More recently, it became clear that the anti-tumor activity of PI3K inhibitors might not be due only to a direct effect on the cancer cells but it can also be mediated via inhibition of the kinases in non-neoplastic cells present in the tumor microenvironment. T-cells represent an important component of the tumor microenvironment and they comprise different subpopulations that can have both anti- and pro-tumor effects. In this review article, we discuss the effects that PI3Kδ inhibitors exert on the immune system with a particular focus on the T-cell compartment.
Open AccessPI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma patients and PI3Kδ inhibitors are already approved by regulatory agencies. More recently, it became clear that the anti-tumor activity of PI3K inhibitors might not be due only to a direct effect on the cancer cells but it can also be mediated via inhibition of the kinases in non-neoplastic cells present in the tumor microenvironment. T-cells represent an important component of the tumor microenvironment and they comprise different subpopulations that can have both anti- and pro-tumor effects. In this review article, we discuss the effects that PI3Kδ inhibitors exert on the immune system with a particular focus on the T-cell compartment.